These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9415336)

  • 1. Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
    Fumoleau P; Giovannini M; Rolland F; Votan B; Paillarse JM
    Oral Oncol; 1997 Sep; 33(5):354-8. PubMed ID: 9415336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group.
    Davidson NG; Paska W; Van Belle S; Goedhals L; McQuade B; McRae J
    Oncology; 1997; 54(5):380-6. PubMed ID: 9260599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group.
    Lebeau B; Depierre A; Giovannini M; Rivière A; Kaluzinski L; Votan B; Hédouin M; d'Allens H
    Ann Oncol; 1997 Sep; 8(9):887-92. PubMed ID: 9358940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
    Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
    Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group.
    Krzakowski M; Graham E; Goedhals L; Joly F; Pawlicki M; Rapoport B; Yelle L; Lees J; McQuade B
    Anticancer Drugs; 1998 Aug; 9(7):593-8. PubMed ID: 9773802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
    Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
    J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group.
    Needles B; Miranda E; Garcia Rodriguez FM; Diaz LB; Spector J; Craig J; Cohen G; Krasnow S; Brogden J; Ames M
    Support Care Cancer; 1999 Sep; 7(5):347-53. PubMed ID: 10483821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women.
    Franchi M; Donadello N; Zanaboni F; Tusei A; Scorbati E
    Oncology; 1995; 52(6):509-12. PubMed ID: 7478441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
    Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
    J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
    de Wit R; Beijnen JH; van Tellingen O; Schellens JH; de Boer-Dennert M; Verweij J
    Br J Cancer; 1996 Jul; 74(2):323-6. PubMed ID: 8688345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.
    Brock P; Brichard B; Rechnitzer C; Langeveld NE; Lanning M; Söderhäll S; Laurent C
    Eur J Cancer; 1996 Sep; 32A(10):1744-8. PubMed ID: 8983284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
    Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
    Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.
    Chevallier B; Marty M; Paillarse JM
    Br J Cancer; 1994 Dec; 70(6):1171-5. PubMed ID: 7981071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
    Grunberg SM; Lane M; Lester EP; Sridhar KS; Mortimer J; Murphy W; Sanderson PE
    Cancer Chemother Pharmacol; 1993; 32(4):268-72. PubMed ID: 8324868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.
    Stewart A; McQuade B; Cronje JD; Goedhals L; Gudgeon A; Corette L; Froger X; Tubiana-Hulin M; Laplaige P; Roberts JT
    Oncology; 1995; 52(3):202-10. PubMed ID: 7715904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
    Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
    Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.